{"doi":"10.1248/cpb.36.3557","title":"Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes.","abstract":null,"journal":"Chemical and Pharmaceutical Bulletin","year":1988,"id":625163,"datarank":0.4636563680037475,"base_score":3.091042453358316,"endowment":3.091042453358316,"self_citation_contribution":0.4636563680037475,"citation_network_contribution":0.0,"self_endowment_contribution":0.4636563680037475,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":21,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1616464,"name":"TOMOAKI IWASA","orcid":null,"position":1,"is_corresponding":false},{"id":1616466,"name":"JIRO FUJISAKI","orcid":null,"position":2,"is_corresponding":false},{"id":1616467,"name":"SEIJI SAWAI","orcid":null,"position":3,"is_corresponding":false},{"id":1616468,"name":"AKIRA KAGAYAMA","orcid":null,"position":4,"is_corresponding":false},{"id":1616462,"name":"YUJI TOKUNAGA","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes.","abstract":"Various types of unilamellar liposomes possessing a narrow size distribution were prepared by controlled dialysis and their blood clearance was studied in mice and rats to assess their suitability as drug carriers for intravenously injectable liposomal sustained-release delivery systems. Also, the utility of these liposomal carrier systems combined with lipophilic prodrugs of mitomycin C (MMC) was evaluated. The fate of the liposomes was monitored uisng N-4-nitrobenzo-2-oxa-1, 3-diazole-dipalmitoylphosphatidylethanolamine (NBD-PE), a liposomal membrane marker. The effect of vesicle size on the blood clearance was investigated for neutral liposomes. Small-sized (S-) liposomes (90±15 nm) were cleared slowly compared with medium-sized (M-) liposomes (181±31 nm) and large-sized liposomes (281±38 nm). Surface charge was also an important determinant of the disposition of small-sized liposomes. S-Liposomes were retained in the circulation longer than positively (S+-) and negatively (S--) charged liposomes. The integrity of S-liposomes in the circulation was examined by simultaneous determination of NBD-PE and carboxyfluorescein (CF) entrapped in the liposomal membrane and liposomal aqueous phase, respectively. CF administered in the liposome-encapsulated form was cleared slowly in a fashion similar to NBD-PE, while free CF, administered as an aqueous solution, was rapidly removed from the circulation. These results reveal that S-liposomes show the best pharmacokinetic properties as a carrier vehicle for intravenously injectable sustained-release delivery systems. S-Liposomes loaded with the lipophilic MMC prodrug, N-(cholesteryloxycarbonyl)glycyl MMC or cholesteryloxyacetyl MMC, successfully gave sustained blood levels of the parent drug following intravenous injection. Thus, the potential utility of MMC prodrug-bearing S-liposomes as an intravenously injectable MMC sustained-release dosage form was demonstrated.","is_dataset_classified":null,"base_score":3.091042453358316,"endowment":3.091042453358316,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"3149214","pmcid":null,"openalex_id":"https://openalex.org/W1965976865","authors":[],"funders":[],"total_grants":0,"fwci":0.5327,"citation_percentile":0.61901596,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2016,"count":1},{"year":2018,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://www.jstage.jst.go.jp/article/cpb1958/36/9/36_9_3557/_pdf","host_type":"journal"},{"url":"https://www.jstage.jst.go.jp/article/cpb1958/36/9/36_9_3557/_pdf","host_type":"publisher"},{"url":"http://www.jstage.jst.go.jp/article/cpb1958/36/9/36_9_3557/_pdf","host_type":"publisher"},{"url":"https://doi.org/10.1248/cpb.36.3557","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/3149214","host_type":"repository"}],"fields_of_study":["Nanoparticle-Based Drug Delivery","RNA Interference and Gene Delivery","Lipid Membrane Structure and Behavior"],"mesh_terms":["Animals","Chromatography, High Pressure Liquid","Delayed-Action Preparations","Female","Injections, Intravenous","Liposomes","Male","Mice, Inbred ICR","Mitomycins","Prodrugs","Rats, Inbred Strains","Drug Design","Mitomycin","Mice","Rats"],"keywords":["Liposome","Chemistry","Pharmacokinetics","Prodrug","Drug carrier","Pharmacology","Clearance","Drug delivery","Vesicle","Chromatography","Dosage form","Membrane","Biochemistry","Medicine","Organic chemistry"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T05:58:45.310997Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}